Recordati Stock - Sunday background on the specialty pharma group

Recordati stock gets a Sunday background check: how the Italian specialty pharma group earns its money, where consensus stands, and what investors should know about the rare-disease portfolio and upcoming events.

Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 07:39 CET. Details in the imprint.

Recordati (IT0003828271) is a long-established Italian specialty pharmaceutical group listed in Milan. With no fresh ad-hoc news this weekend, the focus today is on background: strategy, portfolio, balance sheet and where the stock stands in the European pharma landscape.

What the latest figures show

Recordati published its latest full-year results for 2024 in early 2025, confirming the group's positioning as a profitable, mid-sized European pharma player. According to the company's annual results materials, 2024 revenue reached roughly EUR 2.1 billion, with solid growth versus the prior year.

The same 2024 communication shows adjusted EBITDA climbing to around EUR 825 million, implying a robust margin in the high-30% range. Net profit attributable to shareholders stood in the mid-hundreds of millions of euros, underlining a consistently cash-generative profile.

Sunday focus on background and management

Founded in Milan in 1926, Recordati has evolved from a national pharmaceutical laboratory into an international specialty pharma and rare-disease group with operations in more than 150 countries. The company still keeps its corporate headquarters in Milan, while manufacturing is spread across several European sites.

The current governance structure combines a board with independent directors and experienced pharma executives, supported by a management team that has emphasized bolt-on acquisitions to widen the rare-disease portfolio. Private equity investor CVC Capital Partners became the controlling shareholder in 2022, but the company remains listed on the Italian market.

The product behind the stock

Recordati generates revenue in two main areas: specialty and primary care medicines, and a growing rare-disease franchise. Flagship products include antihypertensive drug Zanidip and several rare-disease therapies, among them Carbaglu for the treatment of a rare urea cycle disorder.

Where the stock trades today

The shares of Recordati (IT0003828271) trade on the Italian market (Euronext Milan) at around EUR 50 per share as of 06/21/2026, 07:39 CET.

Key facts on Recordati stock

• Company: Recordati S.p.A.
• ISIN: IT0003828271
• WKN: 870239
• Ticker: REC
• Venue: Euronext Milan
• Price (as of 06/21/2026, 07:39 CET): 50.00 EUR
• Market cap: 10,000,000,000 EUR (as of 06/21/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: FTSE MIB
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.